Income StatementBalance SheetCash FlowSegments
MPLX logo

MPLX Cash Flow Statement

Operating, investing, and financing cash movements

MPLX generated $6.0B in operating cash flow over the trailing twelve months. After $2.1B in capital expenditures, free cash flow was $3.9B. Free cash flow decreased 0.2% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$6.0BNet Cash From Investing (TTM)-$5.1BNet Cash From Financing (TTM)-$2.0BCapital Expenditures (TTM)$2.1B
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$54.8B
P/E Ratio11.57

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$0.0$237.0M$0.0$3.1B$0.0-$14.0M
Capital expenditures$308.0M$267.0M$301.0M$526.0M$714.0M$575.0M
Proceeds from Sale of Assets (Investing)$1.0M$1.0M$0.0$0.0$974.0M$4.0M
Net cash from investing activities-$349.0M-$601.0M-$602.0M-$3.7B$0.0-$791.0M
Dividend Received from Consumer Healthcare JV$8.0M$21.0M$39.0M$83.0M$150.0M$0.0
Payment for (Proceeds from) Other Investing Activity$0.0$0.0-$8.0M-$100.0M—-$4.0M
Payments to Acquire Interest in Joint Venture—$119.0M$348.0M$309.0M$232.0M$238.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in related party receivables-$107.0M$35.0M-$135.0M-$5.0M-$21.0M$25.0M
Change in accounts payable$59.0M-$76.0M$71.0M-$33.0M—-$15.0M
Change in accounts receivable-$42.0M$100.0M-$132.0M-$12.0M-$4.0M$24.0M
Change in inventories$9.0M$6.0M$6.0M$7.0M$7.0M$6.0M
Other working capital changes—-$2.0M$6.0M$0.0-$5.0M$11.0M
Change in Derivative Assets and Liabilities$10.0M-$4.0M$7.0M$4.0M$10.0M-$64.0M
Net cash from operating activities$1.7B$1.2B$1.7B$1.4B$1.5B$1.3B
Net income$1.1B$1.1B$1.1B$1.6B$1.2B$922.0M
Non-cash interest expense$13.0M$10.0M$6.0M$7.0M$7.0M$7.0M
Cost Of Goods And Services Sold Depreciation And Amortization$324.0M$326.0M$324.0M$346.0M$355.0M$358.0M
Distributions of earnings from equity method investees$230.0M$188.0M$207.0M$236.0M$233.0M$237.0M
Gain (Loss) on Disposition of Assets-$750.0K$0.0$0.0$1.0M$160.0M-$1.0M
Gain on equity method investment$5.0M$121.0M$121.0M$121.0M$121.0M—
Equity in earnings (losses) of equity method investees$171.0M$186.0M$170.0M$186.0M$155.0M$182.0M
Deferred revenue-$7.0M-$12.0M-$21.0M-$19.0M-$22.0M-$1.0M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net Change in Cash Excluding Exchange Rate Effect—$1.0B-$1.1B$379.0M$372.0M-$631.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from issuance of debt$0.0$2.0B$1.0M$4.6B$0.0$1.5B
Repayments of debt$1.2B$500.0M$1.2B$762.0M$0.0$1.5B
Distributions to noncontrolling interests—$11.0M$11.0M$11.0M—$11.0M
Net cash from financing activities-$2.2B$370.0M-$2.3B$2.7B-$1.2B-$1.2B
Repurchases of common stock$100.0M$100.0M$100.0M$100.0M$100.0M$50.0M
Distribution Made to Limited Partner, Cash Distributions Paid$974.0M$972.0M$976.0M$975.0M$1.1B$1.1B
Payments Of Debt Issuance Costs$0.0$19.0M$1.0M$42.0M$1.0M$15.0M
Payments of Ordinary Dividends, Preferred Stock and Preference Stock—$6.0M$0.0$0.0——
Contributions from parent$9.0M$7.0M$7.0M$6.0M$4.0M$4.0M
Other, net-$1.0M-$6.0M$0.0$0.0—-$6.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.4B$979.0M$1.4B$905.0M$782.0M$772.0M